In a CRC-PDO (Stage I-IV) biobank, gene–drug response studies showed that RAS/RAF mutations serve as a signature for predicting sensitivity to cetuximab (an EGFR inhibitor) [26]. The gene discussed is EGFR; the disease is colorectal carcinoma.